| POTENTIAL PHARMACOLOGICAL TARGETS |
|
| Year : 2020 | Volume
: 52
| Issue : 3 | Page : 222-226 |
Target/therapies for chronic recurrent erythema nodosum leprosum
Pugazhenthan Thangaraju1, Shoban Babu Varthya2, Sajitha Venkatesan1
1 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
2 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
Correspondence Address:
Dr. Pugazhenthan Thangaraju
Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_788_19
A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.
[FULL TEXT] [PDF]*
|
